Better Therapeutics to Attend Chardan Digital Prescription Therapy Virtual Summit | News

0

SAN FRANCISCO–(BUSINESS WIRE)–April 4, 2022–

Best Therapeutics, Inc. (NASDAQ: BTTX), a digital prescription therapy (PDT) company developing nutritional cognitive-behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, co-founder and CEO, will participate in a fireside chat at Chardan’s Digital Prescription Therapy Virtual Summit on Monday, April 11, 2022 at 1:30 p.m. EST.

A live webcast will be available in the Presentations and Events section of the Better Therapeutics Investor Site for approximately 90 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapy (PDT) company developing a new form of cognitive behavioral therapy to address the root causes of cardiometabolic disease. The company has developed a proprietary platform for the development of FDA-regulated software solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in the neural pathways of the brain so that lasting behavioral changes become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while reducing healthcare costs. Better Therapeutics’ clinically validated mobile apps are intended to be prescribed by doctors and reimbursed like traditional medicines.

For more information visit: bettertx.com.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220404005846/en/

CONTACT: Investor Relations:

Marc Heinen

[email protected]:

Ryan McKenna at Real Chemistry

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: DIABETES HEALTH MENTAL HEALTH CARDIOLOGY

SOURCE: Better Therapeutics, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 04/04/2022 16:05 / DISK: 04/04/2022 16:06

http://www.businesswire.com/news/home/20220404005846/en

Copyright BusinessWire 2022.

Share.

Comments are closed.